Compound
← Compound
Official website →
ONCBeOne Medicines Ltd.
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- ONC
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of vari…
IndustryBiotechnology
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
26.74×
P/B
Price divided by book value
11.23×
EV/EBITDA
Enterprise value divided by operating cash generation
34.48×
EV/Revenue
Enterprise value divided by revenue
6.16×
What the company earns
ROE
Return on shareholders’ equity
14.3%
ROA
Return on all assets
7.2%
Gross margin
What remains after product costs
87.8%
Operating margin
What remains after operating the business
15.1%
Net margin
How much of each revenue unit becomes profit
10.7%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.22
Total debt
Sum of borrowings
$1.14B
Cash
Cash available to cover it
$5.1B
Current ratio
Short-term assets divided by short-term liabilities
3.4
Free cash flow
Cash left after investing
$595.89M
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.52
Revenue growth
Compared with the same period a year earlier
29.6%
Earnings growth
Compared with the same period a year earlier
151.3%
Dividend yield
Trailing 12-month distributions divided by price
0%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 1.42B | 2.46B | 3.81B | 5.34B |
| Lucro bruto | 1.13B | 2.08B | 3.22B | 4.67B |
| Despesas com vendas e administrativas | -1.28B | -1.51B | -1.83B | -2.08B |
| Pesquisa e desenvolvimento | -1.64B |
News about ONC
Motley Fool · 3 days ago
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Investing Brasil · 4 days ago
Orbis Medicines fecha acordo de US$ 1,4 bi com Novo Nordisk
Investing.com · 4 days ago
Orbis Medicines partners with Novo Nordisk on $1.4bn drug deal
Motley Fool · 5 days ago
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
Yahoo Finance · 5 days ago
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
Follow ONC and get agent analysis of what is moving the stock.
Open Compound